Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication  by Murphy, Christopher M. et al.
ReportHepatitis B Virus X Protein Promotes Degradation of
SMC5/6 to Enhance HBV ReplicationGraphical AbstractHighlightsd HBx interacts with SMC5/6 complex proteins
d HBx/HBV infection leads to SMC5/6 degradation in human
hepatocytes
d HBx targets SMC5/6 for ubiquitylation and degradation by
the DDB1-CUL4-ROC1 E3 ligase
d Knockdown of SMC5/6 rescues replication of HBx-deficient
HBV virusMurphy et al., 2016, Cell Reports 16, 2846–2854
September 13, 2016 ª 2016 The Authors.
http://dx.doi.org/10.1016/j.celrep.2016.08.026Authors
Christopher M. Murphy, Yanping Xu,
Feng Li, ..., Yanbao Yu, Yue Xiong,
Lishan Su
Correspondence
yxiong@email.unc.edu (Y.X.),
lsu@med.unc.edu (L.S.)
In Brief
Murphy et al. find that HBx-redirected
CRL4 E3 ligase activity targets SMC5/6.
SMC5/6 inhibits HBV gene expression,
and SMC5/6 depletion rescues HBx-
deficient HBV replication, indicating that
SMC5/6 is counteracted by CRL4HBx-
mediated SMC5/6 degradation.Accession NumbersPXD004762
Cell Reports
ReportHepatitis B Virus X Protein Promotes Degradation
of SMC5/6 to Enhance HBV Replication
Christopher M. Murphy,1,2,5 Yanping Xu,1,3,5 Feng Li,1,2,5 Kouki Nio,1,2 Natalia Reszka-Blanco,1,2 Xiaodong Li,1,2
Yaxu Wu,1,2 Yanbao Yu,4 Yue Xiong,1,3,* and Lishan Su1,2,6,*
1Lineberger Comprehensive Cancer Center
2Department of Microbiology and Immunology
3Department of Biochemistry and Biophysics
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
4J. Craig Venter Institute, 9714 Medical Center Drive, Rockville, MD 20850, USA
5Co-first author
6Lead Contact
*Correspondence: yxiong@email.unc.edu (Y.X.), lsu@med.unc.edu (L.S.)
http://dx.doi.org/10.1016/j.celrep.2016.08.026SUMMARY
The hepatitis B virus (HBV) regulatory protein X (HBx)
activates gene expression from the HBV covalently
closed circular DNA (cccDNA) genome. Interaction
of HBx with the DDB1-CUL4-ROC1 (CRL4) E3 ligase
is critical for this function. Using substrate-trapping
proteomics, we identified the structural maintenance
of chromosomes (SMC) complex proteins SMC5 and
SMC6 as CRL4HBx substrates. HBx expression and
HBV infection degraded the SMC5/6 complex in hu-
man hepatocytes in vitro and in humanized mice
in vivo. HBx targets SMC5/6 for ubiquitylation by
the CRL4HBx E3 ligase and subsequent degradation
by the proteasome. Using a minicircle HBV (mcHBV)
reporter system with HBx-dependent activity, we
demonstrate that SMC5/6 knockdown, or inhibition
with a dominant-negative SMC6, enhance HBx
null mcHBV-Gluc gene expression. Furthermore,
SMC5/6 knockdown rescued HBx-deficient HBV
replication in human hepatocytes. These results indi-
cate that a primary function of HBx is to degrade
SMC5/6, which restricts HBV replication by inhibiting
HBV gene expression.
INTRODUCTION
Hepatitis B virus (HBV) infection causes chronic hepatitis B in an
estimated 350 million people worldwide, putting these people at
high risk for developing liver cirrhosis and, eventually, hepatocel-
lular carcinoma (HCC) (Dienstag, 2008; Revill et al., 2016; Sca-
glione and Lok, 2012). HBV is a partially double-stranded DNA
virus that belongs to the Hepadnaviridae family (Seeger et al.,
2007). After entry into host cells, the viral genome is transported
into the nucleus and converted to a covalently closed circular
DNA (cccDNA), which is the transcription template for all HBV
viral RNAs. Currently available HBV therapeutics, including inter-2846 Cell Reports 16, 2846–2854, September 13, 2016 ª 2016 The A
This is an open access article under the CC BY license (http://creativeferon-a and antiviral drugs, fail to eradicate the cccDNA reservoir
from infected hepatocytes, despite suppressing new viral DNA
replication. Failure to repress or eliminate this cccDNA results
in viral rebound after therapy (Nassal, 2015; Revill et al., 2016;
Zeisel et al., 2015).
The HBV-encoded regulatory protein hepatitis B virus X pro-
tein (HBx) stimulates HBV gene expression from the cccDNA
template, but themechanism by which HBx facilitates HBV repli-
cation remains unclear (Keasler et al., 2007; Leupin et al., 2005;
Slagle and Bouchard, 2016; Tang et al., 2005). HBx interacts with
several cellular proteins and may mediate its role in virus replica-
tion through these interactions. The best characterized HBx
binding partner is the damage-specific DNA-binding (DDB)
protein 1 (DDB1) (Lee et al., 1995; Sitterlin et al., 1997). The inter-
action between HBx and DDB1 is conserved among the HBx
proteins from all mammalian hepadnaviruses and woodchuck
hepatitis virus (WHV) X protein (Sitterlin et al., 1997). This binding
is essential for HBV replication (Hodgson et al., 2012; Leupin
et al., 2005). HBx has been shown to enhance HBV gene expres-
sion from episomal cccDNA. However, the mechanism and
functional significance of HBx-DDB1 interaction during infection
remain elusive.
Initially discovered as a DNA repair factor, DDB1 is now recog-
nized to mainly function as a linker protein for the assembly of
a large number of Cullin 4-ROC1 RING E3 ubiquitin ligase
(CRL4) complexes (Angers et al., 2006; He et al., 2006; Higa
et al., 2006; Jin et al., 2006). DDB1 bridges CUL4 to individual
DDB1-binding WD40 proteins (DWDs, or DDB Cullin-associated
factors; DCAFs), which, in turn, recruit substrates to the CUL4-
ROC1 catalytic core for subsequent ubiquitination (reviewed in
Jackson and Xiong, 2009; Lee and Zhou, 2007). A structural
study has revealed that HBx, although lacking a typical WD40
domain as found in other DWD/DCAF proteins, contains an a-he-
lical motif termed the H-box that is shared by several DWD pro-
teins and some viral proteins and directly binds to DDB1 (Li et al.,
2010). These findings suggest that HBx may assemble an HBx-
DDB1-CUL4-ROC1 E3 ligase complex (referred to as CRL4HBx
hereinafter) to target host proteins that antagonize HBV replica-
tion for ubiquitylation and degradation. This study aims touthors.
commons.org/licenses/by/4.0/).
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D Figure 1. Identification of CRL4-HBx Sub-
strates by TAP/MS and CRL Inhibition
(A) Experimental design to identify the substrate
of CRL4HBx. HepG2 cells inducibly expressing
FLAG-SBP-HBx were induced with doxycycline
and treated with MLN4924 to stabilize HBx-sub-
strate interactions, which were then purified and
analyzed by LC-MS/MS.
(B) Spectral counts of proteins identified under
each condition were compared to identify poten-
tial CRL4HBx substrates. Upper table: HBx in-
teractions with the CRL4 E3 ligase. Lower table:
proteins identified either exclusively or in greater
amounts with MLN4924 treatment relative to
DMSO are shown (potential substrates). The
table shows the combined results from two
separate experiments. For proteins identified in
both experiments, the mean number of spectral
counts is listed.
(C) Substrate candidates were screened for HBx-
induced instability 5 days after induction of HBx
expression with 500 ng/ml doxycycline.
(D) HEK293T cells were cotransfected with
constructs expressing 3xFLAG-HBx, V5-tagged
SMC5/6, or empty vector controls. After 41 hr,
cells were treated, or not treated, with 1 mM
MLN4924 and harvested 10 hr later. Total cell ly-
sates (top) or FLAG immunoprecipitates (bottom)
were then analyzed for the indicated proteins.
(E) HepG2 cells inducibly expressing FLAG-SBP-
HBx (FSH8) were briefly induced with 120 ng/ml
doxycycline for 24 hr, and endogenous SMC5/6
was co-immunoprecipitated with HBx using anti-
FLAG resin. Unmodified HepG2 cells (G2) were
used as a negative control.identify substrates of the CRL4HBx E3 ligase that function as host
restriction factors to inhibit HBV replication.
RESULTS
Identification of HBx Substrates by Substrate-Trapping
Proteomics
To identify the substrate of CRL4HBx, we performed tandem af-
finity purification (TAP) of HBx from a stable HepG2 cell line
that inducibly expresses a biologically active HBx with N-termi-
nal FLAG and streptavidin-binding peptide (SBP) tags (Figure 1A;
Figures S1A–S1C). Because HBx functions as part of an active
E3 ligase, we reasoned that HBx binding to its substrate is tran-
sient, which results in the latter’s degradation, preventing direct
identification of the substrate through binding. Therefore, we
treated cells with MLN4924, an inhibitor of Cullin-RING ligases
that prevents enzymatic activity by preventing neddylation of
the cullin subunit. Inhibition of CRL4 activity in this manner has
been successfully used to identify CRL4 ubiquitylation sub-Cell Reportsstrates (e.g., Emanuele et al., 2011;
Tan et al., 2013). HBx expression was
induced at low levels for 24 hr by the addi-
tion of doxycycline, and then cells were
treated with either MLN4924 to stabilizeHBx-substrate interactions or DMSO as a control. HBx-interact-
ing proteins were then purified by sequential anti-FLAG and
streptavidin binding, and tryptic peptides were analyzed by
liquid chromatography-tandem mass spectrometry (LC-MS/
MS). This analysis, as expected, identified many components
of the HBx-CRL4 complex, including DDB1, CUL4A, and
CUL4B, and six subunits of COP9/signalosome, indicating that
HBx assembles into active CRL4 complexes. Since CUL4A
and CUL4B are localized preferentially in the cytoplasm and
the nucleus, respectively (Nakagawa and Xiong, 2011), this result
also suggests that HBx can form CRL4 complexes in both
subcellular compartments.
To identify potential substrates of HBx, we compared the list
of proteins and looked for those that were identified exclusively,
or with increased abundance, in the MLN4924-treated samples
relative to the DMSO controls. While similar amounts of DDB1,
CUL4A, and CUL4B proteins were present regardless of
MLN4924 treatment, a relatively small number of proteins that
exhibited this behavior were identified (Figure 1B). Notably,16, 2846–2854, September 13, 2016 2847
among these candidates were four separate subunits of a single
protein complex, structural maintenance of chromosomes 5/6
(SMC5/6)—SMC5, SMC6, NSMCE4A, and NDNL2—as well as
other proteins implicated in antiviral defense, including NLRC4,
DDX5, and DHX9.
To determine which, if any, of these candidates were sub-
strates of CRL4HBx ligase, we compared the stability of each
candidate in the absence and presence of HBx. HepG2 cells in-
ducibly expressing HBx (Figures S1D and S1E) were treated with
doxycycline for 5 days to activate HBx expression, and cells
were then analyzed by western blot with antibodies recognizing
the endogenous proteins. Most proteins were unchanged in the
presence of HBx, but three of the tested proteins—SMC6,
SMC5, andNSMCE4A—showed a clear decrease in abundance,
suggesting that SMC5/6 may be a substrate of HBx (Figure 1C).
To confirm the interaction of HBx with SMC5/6 proteins,
we examined whether HBx binds to SMC5/6 by immunoprecip-
itation (IP)-western blot analysis after transient transfection of
3xFLAG-HBx into HEK293T cells. In addition to DDB1, both
ectopically expressed SMC5 and SMC6 were detected in the
HBx immunoprecipitate (Figure 1D). Using antibodies that
recognize SMC5/6, we observed that endogenous SMC5/6
was also bound and degraded by HBx in HepG2 cells after in-
duction of HBx expression (Figure 1E). This degradation was
dose dependent (Figure 2A) and occurred within 2 days of HBx
induction (Figure 2B).
HBV Infection Degrades SMC5/6 Proteins in Human
Hepatocyte Cell Lines and HBV-Infected Human Liver
Tissue in Humanized Mice In Vivo
Next, we used HepG2 cells expressing the HBV receptor sodium
taurocholate cotransporting polypeptide (NTCP) to determine
the activity of HBx in promoting SMC5/6 degradation in cells in-
fected with HBV (Iwamoto et al., 2014). We detected reduced
levels of SMC6 in HBV+ cells by co-staining the HBV core
and SMC6 (Figure 2E). Importantly, we also observed greatly
reduced levels of SMC5/6 in the human liver tissue of HBV-in-
fected NRG Fah humanized mice (Figure 2F) (Li et al., 2014).
Together, these results indicate that HBx induces SMC5/6
degradation in HBV-infected cells.
HBx Degrades SMC5/6 in a CRL4HBx- and Proteasome-
Dependent Manner
To determine whether HBx regulates SMC5/6 degradation via
the CRL4HBx E3 ligase, we examined the effect of knocking
down DDB1, CUL4A, or CUL4B on HBx-induced SMC5/6
degradation (Figure 2C). Knockdown of either DDB1 or a combi-
nation of CUL4A and CUL4B completely blocked HBx-induced
SMC5/6 degradation, and individual knockdown of either
CUL4A or CUL4B, which are functionally redundant, partially
blocked SMC5/6 degradation. Furthermore, this degradation
was sensitive to the proteasome inhibitor MG132 (Figure 2D).
These results suggest that CRL4 is the principal E3 ligase for
HBx-promoted SMC5/6 degradation, which occurs by a protea-
some-dependent pathway. Interestingly, while cells form three
structurally and functionally similar heterodimeric SMC com-
plexes (Jeppsson et al., 2014; Menolfi et al., 2015), only
SMC5/6, but not cohesin (SMC1/3) or condensing (SMC2/4),2848 Cell Reports 16, 2846–2854, September 13, 2016was degraded by HBx, suggesting a unique function of
SMC5/6 in antagonizing HBV.
HBx Targets SMC5/6 for Ubiquitylation by CRL4HBx E3
Ligase
To determine whether HBx promotes SMC5/6 degradation by
catalyzing their polyubiquitylation, we first examined the effect
of HBx on SMC5/6 in an in vivo ubiquitylation assay. Hemagglu-
tinin (HA)-ubiquitin, 3xFLAG-HBx, and either myc-SMC5 or myc-
SMC6 were co-transfected into HEK293T cells, and SMC5/6
proteins were isolated by myc antibody pull-down. Both SMC5
and SMC6 showed a strong polyubiquitin ladder that was
dependent upon the expression of HBx, and this effect was
reduced when HBx(R96E), a CRL4-binding deficient mutant,
was used instead. (Figure 3A; Figure S2A). SMC5/6 polyubiqui-
tylation in vivo was clearly reduced by the knockdown of either
CUL4A or CUL4B and nearly abolished by the knockdown of
DDB1 (Figure 3B). Endogenously expressed SMC6 protein ex-
hibited little ubiquitylation, but it was actively ubiquitylated by a
K48-linked polyubiquitin chain upon expression of HBx (Fig-
ure 3C). Together, these results demonstrate that SMC5/6 is
aberrantly ubiquitylated in vivo by the CRL4HBx E3 ligase, which
catalyzes K48-linked polyubiquitylation of SMC5/6, thereby
promoting their degradation by the proteasome pathway.
To investigate whether CRL4HBx E3 complex catalyzes direct
polyubiquitylation of SMC5/6, we performed in vitro ubiquityla-
tion assays using purified components. A robust ubiquitylation
of SMC5 (Figure 3D; Figure S2B) and SMC6 (Figure 3E; Fig-
ure S2B) was observed when either protein was incubated with
a mixture of immunopurified CUL4A and CUL4B E3 complex;
immunopurified HBx protein; recombinant E1, E2, and ubiquitin;
and ATP. A drop-out assay demonstrated that SMC5/6 polyubi-
quitylation is dependent on E1, E2, E3, and HBx. Again, substi-
tution of wild-type HBx with DDB1-binding-deficient R96E
mutant HBx substantially reduced the polyubiquitylation of
both SMC5 and SMC6, providing additional evidence that HBx
bridges SMC5/6 to the DDB1-CUL4A/B-ROC1 E3 ligases for
ubiquitylation.
HBx Counteracts SMC5/6 Activity to Enhance HBVGene
Expression
The principal role of HBx in HBV infection and pathogenesis is
to activate transcription from the HBV cccDNA template. Since
HBx requires DDB1-CRL4 binding for this function, and
SMC5/6 is an HBx-CRL4 substrate, we next tested whether
SMC5/6 degradation played an inhibitory role in HBV cccDNA
activity. For this purpose, we have developed a minicircle HBV
(mcHBV) cccDNA reporter system to measure this activity (Fig-
ures S1F and S1G; Guo et al., 2016). In this system, mcHBV
cccDNA with no residual bacterial plasmid DNA is generated
by a site-specific recombination reaction in bacteria (Kay et al.,
2010). When transfected into HepG2 cells, this mcHBV cccDNA
is packaged into a minichromosome, produces all HBV proteins,
and can generate HBV virions (L.F. and S.L., unpublished data;
Guo et al., 2016). To facilitate monitoring of HBV gene expres-
sion, we have further cloned Gaussia luciferase (GLuc) into the
mcHBV DNA under the control of the HBV core promoter. As is
true for cccDNA during infection, transcription from the reporter
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Figure 2. HBx Expression and HBV Infection Degrades SMC5/6
(A and B) Inducible HepG2-HBx-H5 cells were treated with a range of doxycycline concentrations (A) or for different lengths of time (B), and SMC5 and SMC6
levels were analyzed by immunoblot.
(C) HEK293T cells were first transfectedwith control small interfering RNA (siRNA) or siRNA targeting indicated genes for 24 hr and transfected with FLAG-HBx for
another 24 hr, followed by immunoblot analysis. Scr., scrambled siRNA (control).
(D) HEK293T cells were transfected with FLAG-tagged HBx for 24 hr and then treated with MG132 (2 mM) for 24 hr, followed by cell lysis and SDS-PAGE.
(E) Confocal microscopy of mock- and HBV-infected human hepatocytes stained with SMC6 (red) and HBc (green) antibodies and counterstained with
DAPI. A representative view is shown, and arrows indicate cells where SMC6 is degraded by HBV infection. Scale bars, 20 mm. Intensities of nuclear SMC6
fluorescence were quantified from HBc+ and HBc cells of multiple fields using ImageJ software. The relative SMC6 level in HBc+ cells was normalized
to that of HBc cells in the same view field. The average of relative SMC6 intensity was calculated from 18 HBc+ and 18 HBc cells. ***p < 0.001 (t test); bars,
SEM. WT, wild-type.
(F) Liver samples fromNRG-FAH-hu hepatocytemicewith human liver reconstitution (>60%human reconstitution) were analyzed for SMC6 levels by immunoblot
in the presence or absence of HBV infection. HBV titers for mice #3 and #4 were 7.47 3 1011/ml and 2.73 3 108 GE per ml, respectively.mcHBV-GLuc DNA is strongly dependent upon HBx (Figure S1I).
Transfection of mcHBV-GLuc reporter cccDNA produced highly
stable luciferase activity (Figure S1H), whereas transfection of an
HBx-deficient form of the mcHBV-GLuc cccDNA showed a
decrease over 4-fold in activity, which could be rescued back
to wild-type levels by expression of HBx in trans (Figure S1I).If HBx-mediated destruction of SMC5/6 promotes transacti-
vation of mcHBV-GLuc cccDNA, then experimental depletion
of SM5/6 should rescue HBx deficiency. To test this, mcHBV re-
porter cccDNAwith amutant HBx gene (DX) was transfected into
inducible HepG2-HBx cells. In the absence of HBx induction,
gene expression activity from the DX mcHBV cccDNA wasCell Reports 16, 2846–2854, September 13, 2016 2849
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Figure 3. SMC5/6 Is a Direct Ubiquitylation Substrate of CRL4-HBx
(A) Wild-type, but not DDB1-binding-deficient R96E mutant, HBx promotes SMC5 and SMC6 polyubiquitylation in vivo. HEK293T cells were transfected with the
indicated plasmids and treated with MG132 4 hr before harvest. Whole-cell lysates were prepared under denaturing conditions, and ubiquitylation (Ub) of SMC5
and SMC6 was examined by coupled IP-western blot analysis.
(B) Knockdown of DDB1, CUL4A, or CUL4B inhibits HBx-promoted SMC5 and SMC6 polyubiquitylation in vivo. HEK293T cells were first transfected with
indicated siRNA oligonucleotides for 24 hr, then transfectedwith plasmids expressing the indicated proteins for another 48 hr, and treatedwithMG132 4 hr before
harvest. Knockdown was verified by immunoblotting with whole-cell lysate. In vivo, SMC5 or SMC6 ubiquitylation was determined by IP-western blot analysis
under denaturing conditions.
(C) HEK293T cells were transfected with indicated plasmids and treated with MG132 before harvest. Whole-cell lysates were prepared under denaturing
conditions. Endogenous SMC6 was precipitated using a SMC6 antibody (Ab.), and the ubiquitylation was examined by western blot analysis using an antibody
recognizing K48-linked polyubiquitin chain.
(D and E) Wild-type (WT), but not DDB1-binding-deficient R96E mutant, HBx promotes SMC5 and SMC6 polyubiquitylation by the CRL4 E3 ligase in vitro.
Immunopurified SMC5 (D) or SMC6 (E) protein was incubated with a mixture of CUL4A and CUL4B immune-complexes and purified HBx in a buffer containing
recombinant ubiquitin, E1, E2, and ATP. Reactions were terminated by the addition of SDS loading buffer, followed by SDS-PAGE and immunoblot with the
indicated antibodies.very low but could be rescued by HBx induction (Figure 4A).
When SMC6 or SMC5 was knocked down by short hairpin
RNA (shRNA) transduction, gene expression from the HBx2850 Cell Reports 16, 2846–2854, September 13, 2016mutant mcHBV-GLuc was completely rescued, indicating that
targeting SMC5/6 is likely a primary cause of HBx-mediated
transactivation of mcHBV cccDNA. This effect was observed
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Figure 4. HBx Targets SMC5/6 to Enhance
HBV Gene Expression and HBV Replication
(A) Knockdown of SMC5 or SMC6 enhances
HBVDX mcHBV-GLuc gene expression. HepG2-
HBx-H5 cells were transfected with HBVDX mini-
circle (mc) cccDNA, subcultured into 96-well
plates, and then transduced with lentivirus en-
coding the shRNA indicated. GLuc activity in the
culture supernatant was analyzed after 14 days.
HBx expression was induced, where indicated,
by the addition of doxycycline (400 ng/ml). RLU,
relative light unit. ***p < 0.001.
(B) Expression of dominant-negative SMC6(K82E)
rescues expression from HBVDX mcHBV-GLuc
cccDNA. HepG2-HBx-H5 cells were co-trans-
fected with HBVDX mcHBV-GLuc cccDNA and
the indicated expression constructs. Luciferase
was assayed after 8 days. ***p < 0.001.
(C–F) Knockdown of SMC5 or SMC6 in HepG2-
NTCP cells enhanced replication of the HBVDX
mutant virus but had little effect on wild-type HBV
virus. HepG2-NTCP cells were transduced with
lentivirus expressing shRNA targeting SMC5,
SMC6, or a non-target control sequence (shCtrl).
After selection, transduced cells were infected
with wild-type or DX HBV. Media were collected
every other day, and HBeAg in the culture media
was analyzed by ELISA at the times indicated
(C and D). HBV replication was further confirmed
by measuring HBsAg by ELISA at 9 days post-
infection (E). ***p < 0.001. The extent to which HBx
promoted HBV replication in each cell line was
calculated by dividing the HBsAg level from wild-
type HBV-infected cells by that from HBVDX-in-
fected cells (F). Bars indicate SEM (A–D) or SD (E).with two separate shRNAs targeting SMC6 or SMC5 (Figure 4A;
Figures S3A and S3B), and it could be partially prevented by
exogenous expression of shRNA-resistant SMC6 bearing silent
mutations in the shRNA target sequence (Figures S3C and
S3D), suggesting that this effect is specific to SMC5/6 function.
In addition, we created a dominant-negative form of SMC6with a
K-to-E point mutation in the ATPase active site (K82E) that pre-
vents DNA binding and SMC5/6 function (Kanno et al., 2015).
Expression of the SMC6(K82E) dominant-negative mutant also
resulted in an increase in mcHBV-GLuc gene expression (Fig-
ure 4B). These results show that SMC5/6 inhibits HBV gene
expression from the HBV cccDNA template and that this function
of SMC5/6 is antagonized by HBx.
Given that SMC6 knockdown could effectively rescue HBx-
deficient mcHBV cccDNA, we next asked to what extent HBxCell Reportscould further stimulate mcHBV-GLuc
gene expression in cells depleted of
SMC6. Doxycycline was added to the
cells to induce HBx expression, and lucif-
erase activity was measured. Compared
with un-induced cells, HBx-induced
transactivation was 5.5-fold in control
cells but only about 1.7-fold in SMC6
knockdown cells (Figures S3E–S3G),
indicating that SMC6 knockdown andHBx expression were performing overlapping functions. The re-
sidual transactivation of HBx in the presence of shRNAs target-
ing SMC6 may be the result of incomplete SMC6 depletion,
though we cannot exclude the possibility that HBx may have
additional, SMC5/6-independent activities in activating tran-
scription from the mcHBV cccDNA template. Nevertheless,
these results indicate that HBx-mediated transactivation of
mcHBV-GLuc gene expression is due, in large part, to its activity
in degrading SMC5/6.
SMC5/6 Knockdown Rescues Infectivity of HBVDX
Mutant Virus in Human Hepatocytes
HBx is essential for productive HBV infection, and HBVDX
mutant has impaired replicative activity in target cells. To further
test whether HBx-targeting of SMC5/6 represents the primary16, 2846–2854, September 13, 2016 2851
function of HBx in enhancing HBV infection and replication, we
next asked whether SMC5/6 knockdown in NTCP+ HepG2 cells
could rescue infection of HBx defective viruses. HepG2-NTCP
cells can support HBV infection, as incubation with HBV results
in the subsequent production of HBsAg and HBeAg, which was
sensitive to the HBV entry inhibitor cyclosporin A (Figures S4A–
S4C). We prepared a set of HepG2-NTCP cell lines transduced
with shSMC6, shSMC5, or a non-targeting control shRNA (Fig-
ure S4G). We then infected these cells with either wild-type
HBV or HBVDX mutant. HBeAg, HBsAg, and HBV DNA were
then monitored to measure HBV infection and replication (Fig-
ures 4C–4F; Figure S4). Wild-type HBV was able to infect all of
the cell lines with similar efficiency, with only a modest increase
in the SMC5 and SMC6 knockdown cells (Figure 4C). HBVDX
mutant, on the other hand, failed to produce detectable levels
of HBV replication in mock-transduced (parental) or short
hairpin control (shCtrl) cells. This defect was efficiently rescued
by SMC6 or SMC5 knockdown, which resulted in levels of
HBV replication (HBeAg levels) that nearly matched those of
wild-type virus (Figure 4D). These findings were confirmed by
measuring HBV HBsAg or HBV genomic DNA in the supernatant
(Figures 4E and 4F; Figures S4D–S4F). Therefore, SMC5/6
knockdown and HBx expression were almost completely redun-
dant with respect to enhancing HBV infection, suggesting that
the principal function of HBx is to degrade the SMC5/6 complex
and counteract its antiviral function.
DISCUSSION
HBx activates HBV viral gene expression from the HBV cccDNA
through a poorly understood mechanism (Slagle and Bouchard,
2016). HBx binds the DDB1 and is proposed to target a host fac-
tor for degradation by the CRL4 E3 ligase (Leupin et al., 2005; Li
et al., 2010; Martin-Lluesma et al., 2008). Here, we identified the
SMC complex proteins SMC5 and SMC6 as the substrates of
CRL4HBx. Importantly, the SMC5/6 complex was degraded by
HBx in human hepatocytes expressing HBx or infected by
HBV. We demonstrate that SMC5/6 knockdown, or inhibition
with a dominant-negative SMC6, enhanced HBx-deficient
mcHBV-GLuc gene expression, indicating that SMC5/6 is a
restriction factor of the HBV cccDNA and is counteracted by
HBx. When tested in NTCP+ human hepatocyte cells that sup-
port HBV infection, SMC5/6 knockdown rescued replication of
HBx-deficient HBV virus but had little effect on wild-type HBV
virus. These results indicate that a primary function of HBx is
to ubiquitylate and degrade SMC5/6, which inhibits HBV replica-
tion by inhibiting HBV cccDNA activity. The results thus reveal a
mechanism for HBx function in HBV-infected cells and provide a
potential avenue for targeting HBV cccDNA function by blocking
HBX-targeted, CRL4-catalyzed SMC5/6 ubiquitylation.
We demonstrate the functional significance of HBx-targeted
SMC5/6 degradation on HBV replication using a physiologically
relevant mcHBV cccDNA system, which is devoid of all bacterial
plasmid DNA and in HBV cccDNA form (Kay et al., 2010). The
mcHBV cccDNA-based assay depended on HBx for maximal
activity and allowed us to study the effect of SMC5/6 and HBx
on cccDNA activity in human hepatocyte cell lines in the absence
of other forms of HBV genomes (Guo et al., 2016). We demon-2852 Cell Reports 16, 2846–2854, September 13, 2016strate that SMC5/6 knockdown, or inhibition with a dominant-
negative SMC6, enhanced HBx-defective mcHBV-GLuc gene
expression. When tested in NTCP+ human hepatocyte cells
that support HBV infection, SMC5/6 knockdown rescued repli-
cation of HBx-deficient HBV virus but had little effect on wild-
type HBV virus. Thus, SMC5/6 is a major restriction factor of
the HBV cccDNA that is counteracted by HBx.
Eukaryotic cells include three functionally related but non-
redundant SMC complexes—cohesins, condensins, and the
SMC5/6 complex—each consisting of SMC heterodimers and
additional non-SMC subunits (Jeppsson et al., 2014). SMC
complexes play a central role in controlling multiple chromatin
processes, such as sister chromatid cohesion, chromosome
condensation, DNA replication, andDNA repair and transcription
(Jeppsson et al., 2014). These functions bear a striking overlap
with some of the multiple reported HBx activities. For example,
HBx, via its DDB1-binding activity, impairs DNA repair (Becker
et al., 1998), S phase progression, chromosome segregation,
and mitosis (Martin-Lluesma et al., 2008). Our finding that HBx
degrades SMC5/6 offers a plausible explanation to these cellular
defects previously linked to HBx. We also note that HBx selec-
tively interacts with and targets for degradation SMC5/6, but
not the other two SMC complexes, suggesting a unique function
of SMC5/6 in inhibiting HBV. This is consistent with the observa-
tions that each SMC complex also has its distinct functions.
While cohesins and condensins are required for establishing
links between sister chromatids and for chromatin compaction,
SMC5/6 plays a role in chromosome segregation and repair.
Loss of SMC5/6 function impairs genome stability and resolution
of replication-induced DNA supercoiling (Kegel et al., 2011). HBx
has been shown to be a cofactor in HCC development. We spec-
ulate that dysregulation of DNA repair and induction of chromo-
somal instability by the expression of HBx may contribute to the
HBV-mediated HCC development.
It will be important to determine how SMC5/6 inhibits cccDNA
function. With its known functions in modulating chromatin
structure and function, it is likely that SMC5/6 suppresses
gene expression from episomal DNA such as HBV cccDNA via
epigenetic mechanisms, and HBx has evolved to counteract
SMC5/6 activity to facilitate HBV replication. The major limitation
of current HBV therapies is the inability to target cccDNA.
SMC5/6 possesses intrinsic DNA-binding activity and was
recently shown to function as an intermolecular linker, bridging
DNA molecules through topological entrapment (Kanno et al.,
2015). This could inhibit cccDNA function by promoting direct
compaction of the cccDNA minichromosome or by tethering it
to inactive or heterochromatic regions of the nucleus. It will be
of great interest to determine exactly how SMC5/6 inhibits
HBV cccDNA function, which could uncover new therapeutic
opportunities for targeting HBV cccDNA and other viruses with
episomal DNA genomes.
A paper reporting the same finding has very recently been
published (Decorsie`re et al., 2016). Although it and the present
study are consistent in the main finding about HBx targeting
SMC5/6, our study additionally contains two important aspects.
First, we provide evidence that SMC5/6 is a direct ubiquitylation
target of HBx-DDB1-CRL4 E3 ligase. Second, we show that of
three functionally related SMC heterodimeric complexes, only
SMC5/6, but not cohesin or condensin complexes, is targeted
by HBx.
EXPERIMENTAL PROCEDURES
IP-MS
HepG2-HBx-FSH8 cells were induced with 120 ng/ml doxycycline for 24 hr,
treated with MLN4924 (1 mM, Cayman Chemical) or DMSO for 4 hr, and lysed
in NP40 lysis buffer (0.5% Nonidet P-40, 50 mM Tris [pH 7.5], 150 mM NaCl)
with Halt Protease Inhibitor Cocktail (Pierce) and DMSO or MLN4924 on ice
after culturing. FLAG-SBP-HBx was precipitated with anti-FLAG M2 resin
(Sigma) affinity eluted with 200 mg/ml 33 FLAG peptide (Sigma). Eluates
were then incubated with streptavidin agarose (GE Life Sciences). Beads
were washed four times with lysis buffer, and peptides were generated by
on-beads trypsin digestion and isolated by filter-aided sample preparation
(FASP). LC-MS/MS was performed as described (Yu and Pieper, 2015).
Data were processed using Proteome Discoverer 1.4 (Thermo Scientific)
with Sequest HT and Mascot algorithms (Yu et al., 2014). Spectral counts
were compared between samples, and those proteins with aR4-fold increase
over negative control runs and that increased after MLN4924 treatment were
selected as potential HBx substrates. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consortium via the PRIDE
partner repository: PXD004762. Anti-FLAG IP for IP-western blot analysis was
performed as described earlier but eluted at 70C for 20 min in SDS-PAGE
loading buffer.
HBV Infection
HepAD38 cells (kindly provided by Dr. J. Hu and Dr. C. Seeger) grown without
doxycyclin, or HepG2 cells transiently transfected with a plasmid encoding
HBVDX (Dr. J. Hu), were grown for 5–7 days (Ladner et al., 1997). Media was
clarified by centrifugation at 10,000 3 g. Supernatants were supplemented
with 10% polyethylene glycol (PEG) 8000, incubated at 21C for 30 min and
4C for 60 min, and centrifuged again. The pellet containing viral particles
was resuspended in 1/100 the original volumewith serum-freemedia and flash
frozen.
For HBV infection, HepG2-NTCP cells (Iwamoto et al., 2014) were plated
at 70%–80% confluency. After 24 hr, media were supplemented with 4%
PEG-8000. HBV was added at 2,000 or 4,000 genome equivalents per cell. Af-
ter 16 hr, cells were rinsed 43 in PBS and cultured in media with 2% DMSO.
Media were collected and changed every 48 hr.
Detection of HBV Replication by ELISA
HBsAg and HBeAg were detected using kits from Alpha Diagnostics and
Abnova, respectively.
Detection of HBc and SMC6 by Immunofluorescence Co-staining
HBV-infected cells were seeded onto coverglasses 9–12 days after infection.
After 24 hr, cells were fixed in 4% paraformaldehyde in PBS, rinsed in PBS,
permeabilized in 0.15% Triton X-100, and then washed three times in
PBS. Blocking buffer (0.2% BSA, 5% donkey serum, 0.1% Triton X-100,
13 PBS [pH 7.4]) was added for 30 min to block nonspecific binding. Primary
antibodies targeting HBc (Zeta) or SMC6 (Abgent) were diluted in blocking
buffer at 1:200 and 1:400, respectively, and incubated with cells for 60 min.
Cells were washed 33 in blocking buffer and then incubated for 60 min with
donkey anti-rabbit Alexa Fluor 488 and donkey anti-mouse Alexa Fluor 594
secondary antibodies (1:1,000, Life Technologies). The coverglasses were
washed in blocking buffer, in PBS, rinsed quickly in ddH20, and mounted
with fluorescence mounting media with DAPI (Abcam).
Luciferase Assays
Cells were cotransfected with mcHBV-Gluc DNA (0.5%) and carrier DNA
(pUC19, 99.5%). The next day, cells were transduced with lentiviruses
expressing shRNA or proteins. Alternatively, cells were cotransfected with
mcHBV-Gluc DNA and the relevant constructs. Media were then collected
every 2 days and assessed for luciferase activity on a GloMax 96 Microplate
Luminometer (Promega).Statistical Analysis
Comparisons were performed using t test or ANOVA with Tukey’s post hoc
test using GraphPad Prism 5 software.
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